Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter

Am J Kidney Dis. 2017 Apr;69(4):553-554. doi: 10.1053/j.ajkd.2016.10.026. Epub 2017 Jan 4.

Authors

Kim Dao¹, Haithem Chtioui², Yimin Lu², Cody J Peer³, William D Figg³, Menno Pruijm², Thierry Buclin², Sébastien Kissling²

Affiliations

¹ Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Electronic address: kim.dao@chuv.ch.
² Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
³ National Cancer Institute, Bethesda, Maryland.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Equipment Design
Humans
Immunologic Factors / pharmacokinetics
Male
Membranes, Artificial*
Middle Aged
Multiple Myeloma / metabolism
Multiple Myeloma / therapy*
Renal Dialysis / instrumentation*
Thalidomide / analogs & derivatives*
Thalidomide / pharmacokinetics

Substances

Immunologic Factors
Membranes, Artificial
Thalidomide
pomalidomide

Grants and funding

ZIC SC006537-20/Intramural NIH HHS/United States